GSK: Exdensur Approved in China for the Treatment of Severe Asthma
March 31, 2026
March 31, 2026
LONDON, England, March 31 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 30, 2026:
* * *
Exdensur (depemokimab) approved in China for the treatment of severe asthma
* Exdensur is the first and only ultra-long-acting biologic in China for the treatment of severe asthma with an eosinophilic phenotype
* Approval based on SWIFT trials showing significantly lower rates of exacerbations in p . . .
* * *
Exdensur (depemokimab) approved in China for the treatment of severe asthma
* Exdensur is the first and only ultra-long-acting biologic in China for the treatment of severe asthma with an eosinophilic phenotype
* Approval based on SWIFT trials showing significantly lower rates of exacerbations in p . . .